Litcius/Paper detail

12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine

Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Pad Chivukula, Ye Zhang, Judd L. Walson

2024The Lancet Infectious Diseases28 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Persistence (discontinuity)Immune systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakMedicineBiologyImmunologyEngineeringInternal medicineInfectious disease (medical specialty)OutbreakDiseaseGeotechnical engineeringSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesAnimal Virus Infections Studies
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine | Litcius